HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization

Modern Pathology

Volumn 14, Issue 11, 2001, Pages 1079-1086

  Thomson, Thomas A ^a   Hayes, Malcolm M ^a   Spinelli, John J ^a   Hilland, Ernie ^a   Sawrenko, Christina ^a   Phillips, Don ^a   Dupuis, Beverley ^b   Parker, Robin L ^c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast carcinoma; c erbB2; Fluorescent in situ hybridization (FISH); HER 2 neu; Immunohistochemistry; Interobserver variability

Indexed keywords

MONOCLONAL ANTIBODY; TRASTUZUMAB;

ANTIBODY SPECIFICITY; ARTICLE; BREAST CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY;

EID: 0035167070     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880440     Document Type: Article

References (19)

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
2. HER-2/neu (c-erb-B2) gene and protein in breast cancer
3. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer
4. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
5. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
6. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
7. C-erbB-2 immunostaining: Problems with interpretation
8. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation
9. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in nodenegative breast carcinomas
10. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
11. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
12. Determination of Her-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization
13. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immnuohistochemistry
14. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma
15. Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?
16. Evaluation of HER-2/neu (erbB-2) status in breast cancer: From bench to bedside
17. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system
18. The HercepTest assay. Another perspective